Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Delaware Health News Online.
Press releases published on August 13, 2025
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 13, 2025
Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveiled a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the …
BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights
GlobeNewswire
·
August 13, 2025
Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and EBITDA guidance Remaining performance …
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
August 13, 2025
Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China Initiated first-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 being developed for acne in …
Nasus Pharma Announces Pricing of $10 Million Initial Public Offering
GlobeNewswire
·
August 13, 2025
TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions …
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
GlobeNewswire
·
August 13, 2025
Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently announced acquisition of LAVA …
LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency
GlobeNewswire
·
August 13, 2025
PASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that its Board of Directors has approved a strategic …
On World Organ Donation Day KFSHRC Announces 10 Kidney Exchange Transplants Completed in 48 Hours
GlobeNewswire
·
August 13, 2025
RIYADH, Saudi Arabia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) successfully performed 10 kidney exchange transplants over two consecutive days, setting a global record for the highest number of such …
Immatics Announces Second Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
August 13, 2025
Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated patients with metastatic melanoma in data from a Phase …
Tilray Medical Forms Strategic Partnership in Italy to Broaden Access to Medical Cannabis Extracts
GlobeNewswire
·
August 13, 2025
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to …
Tilray Medical stringe una partnership strategica in Italia per rendere più accessibili gli estratti di cannabis terapeutica
GlobeNewswire
·
August 13, 2025
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, una divisione di Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) e leader mondiale nel settore della cannabis terapeutica, impegnata a rafforzare l'alleanza terapeutica tra pazienti e …
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 13, 2025
More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC) Plan to report initial clinical data from Emi-Le expansion cohorts in second half of 2025 …
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)
GlobeNewswire
·
August 13, 2025
$15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025 Growth for neffy in the U.S. driven by increased payor access with additional near-term growth anticipated from national direct-to-consumer (DTC) …
Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance
GlobeNewswire
·
August 13, 2025
First Half 2025 Total Revenues were $88.8 Million, up 11% Year-over-Year; Revenues for 2025 Second Quarter were $44.8 Million, up 5% Year-over-Year First Half 2025 Adjusted EBITDA of $22.5 Million, up 35% Year-over-Year and Representing 25% Margin of …
Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)
GlobeNewswire
·
August 13, 2025
Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- …
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
August 13, 2025
Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with $75 Million Equity Financing; Cash Position Expected to …
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
August 13, 2025
– Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with quarterly dosing – — Additional data from the ongoing …
PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update
GlobeNewswire
·
August 13, 2025
Multiple Abstracts Presented at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS …
Inotiv, Inc. to Participate in Three Investor Conferences in September 2025
GlobeNewswire
·
August 13, 2025
WEST LAFAYETTE, Ind., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research …
BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series
GlobeNewswire
·
August 13, 2025
NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO …
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
GlobeNewswire
·
August 13, 2025
U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, enhancing program’s potential for priority review PRECISE-AD Phase 1b Trial in Alzheimer’s Disease Progressing on Schedule: Over 50% enrolled, no cases of ARIA and no patient …